BRITTANY FEVRIER: Open Payments
NPI 1598919219 · RIVERSIDE, RI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,495 in 58 payments from 16 companies in 2025. Trend: 2023 $773 · 2024 $1,352 · 2025 $1,495
Food & beverage: $1,495
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $256 |
| Alexion Pharmaceuticals, Inc. | 6 | $239 |
| Novo Nordisk Inc | 5 | $144 |
| Bayer Healthcare Pharmaceuticals Inc. | 6 | $141 |
| Aurinia Pharma U.S., Inc. | 6 | $123 |
| Fresenius USA Marketing, Inc. | 6 | $107 |
| Travere Therapeutics, Inc. | 3 | $80 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $75 |
| Calliditas Therapeutics US Inc. | 2 | $62 |
| Vifor Pharma, Inc. | 3 | $54 |
Products named: ULTOMIRIS, Ozempic, Kerendia, LOKELMA, LUPKYNIS, VELPHORO, JARDIANCE, TARPEYO.
Industry payments across RI — which companies pay providers there.
